Duration
4 Years
Targeting hope
DNA methylation markers to predict
About METHYLOMIC
METHYLOMIC is committed to bringing personalised treatment-selection in Crohn’s disease and other immune-mediated inflammatory diseases to clinical practice.
Budget
10 Million
18 partners
9 countries
Why METHYLOMIC?
Crohn's disease
The prime purpose of METHYLOMIC is to develop and clinically validate a novel epigenetic biomarker tool that enables the identification of most optimal treatments for individual patients and hence to ensure an effective and efficient use of existing and broadly prescribed biologicals for Crohn´s disease (CD).
Rheumatoid Arthritis
The EPIPSORA trial will be carried out as part of the METHYLOMIC project. This study will investigate whether it is possible to develop and validate an epigenetic biomarker that predicts treatment success for rheumatoid arthritis (RA).
Psoriasis
The EPIPSORA trial will be carried out as part of the METHYLOMIC project. This study will investigate whether it is possible to develop and validate an epigenetic biomarker that predicts treatment success for psoriasis (PsO).